Palopegteriparatide

Palopegteriparatide

Chemical structure of Palopegteriparatide

Palopegteriparatide is a recombinant protein used in the treatment of hypoparathyroidism. It is a modified form of parathyroid hormone (PTH) that is designed to mimic the effects of the naturally occurring hormone in the body. This medication is particularly useful for patients who have low levels of parathyroid hormone, which can lead to a variety of metabolic imbalances.

Mechanism of Action

Palopegteriparatide functions by acting on the same receptors as endogenous parathyroid hormone. It binds to the parathyroid hormone receptors in the body, which are primarily located in the bone and kidney. This binding stimulates the release of calcium from bones into the bloodstream, increases the reabsorption of calcium in the kidneys, and enhances the activation of vitamin D in the kidneys, which in turn increases intestinal absorption of calcium. These actions help to maintain calcium homeostasis in patients with hypoparathyroidism.

Clinical Use

Palopegteriparatide is indicated for the treatment of adults with hypoparathyroidism who cannot be adequately controlled with standard therapy alone. Standard therapy typically includes calcium supplements and active forms of vitamin D, such as calcitriol. By providing a recombinant form of parathyroid hormone, palopegteriparatide helps to address the underlying hormone deficiency.

Administration

The drug is administered via subcutaneous injection, allowing for direct absorption into the bloodstream. The dosing regimen is typically tailored to the individual patient's needs, based on their serum calcium levels and response to therapy.

Side Effects

Common side effects of palopegteriparatide include nausea, headache, and dizziness. As with any medication that affects calcium levels, there is a risk of hypercalcemia, which can lead to symptoms such as muscle weakness, fatigue, and confusion. Monitoring of serum calcium levels is essential during treatment.

Development and Approval

Palopegteriparatide was developed as a therapeutic option for patients with hypoparathyroidism who do not respond adequately to conventional treatments. Its development involved extensive clinical trials to assess its safety and efficacy. The drug has been approved by various regulatory agencies for use in specific patient populations.

Related Pages

• Hypoparathyroidism
• Parathyroid hormone
• Calcium metabolism
• Vitamin D